Tigermed's asset


Tigermed is a contract research company providing whole process clinical trial services for the R&D of pharmaceuticals.


Find anything inaccurate?

If you spot any mistakes on this brand profile, report to us.


Brand Logos

View all
Tigermed's logos





Tigermed is a leading contract research organization (CRO) based in China. The company was founded in 2004 by a group of experienced pharmaceutical industry professionals. Since its establishment, Tigermed has grown rapidly to become one of the largest CROs in China and has expanded its operations globally.

The company's headquarters are located in Hangzhou, China. Hangzhou is a major city in the Zhejiang province, known for its vibrant pharmaceutical industry and research institutions. Tigermed's headquarters not only serve as the administrative center of the company but also house state-of-the-art laboratories and research facilities.

Tigermed offers a wide range of products and services in clinical research and development. The company provides end-to-end solutions for clinical trials, including protocol design, data management, statistical analysis, and regulatory affairs. Tigermed has extensive experience in diverse therapeutic areas, including oncology, neurology, cardiology, and infectious diseases.

In terms of global operations, Tigermed has expanded its presence beyond China. The company has established subsidiaries or partnerships in major pharmaceutical markets such as the United States, the United Kingdom, Australia, and several countries in Europe and Asia. These strategic collaborations have allowed Tigermed to provide services to multinational pharmaceutical companies and conduct global clinical trials.

Tigermed has achieved a strong market position in the contract research field both domestically and internationally. With its comprehensive range of services and global presence, the company has gained a competitive advantage. Tigermed has established long-term partnerships with various pharmaceutical giants such as Pfizer, Novartis, and GSK, enhancing its reputation as a reliable and trusted CRO.

In terms of major events and achievements, Tigermed successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange in 2019. This IPO not only increased the company's capital but also further strengthened its market position. As of the latest updates, Tigermed continues to expand its global footprint and enhance its service offerings.

The company is actively exploring collaborations and partnerships to further drive its growth. With its strong track record and commitment to excellence, Tigermed remains a leading CRO in China and a key player in the global pharmaceutical industry


Brand collections

View all